1
|
Moura DS, Díaz-Martín J, Bagué S, Orellana-Fernandez R, Sebio A, Mondaza-Hernandez JL, Salguero-Aranda C, Rojo F, Hindi N, Fletcher CDM, Martin-Broto J. A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report. Int J Mol Sci 2021; 22:ijms22147514. [PMID: 34299133 PMCID: PMC8305824 DOI: 10.3390/ijms22147514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 06/25/2021] [Accepted: 07/05/2021] [Indexed: 11/29/2022] Open
Abstract
Solitary fibrous tumor is a rare subtype of soft-tissue sarcoma with a wide spectrum of histopathological features and clinical behaviors, ranging from mildly to highly aggressive tumors. The defining genetic driver alteration is the gene fusion NAB2–STAT6, resulting from a paracentric inversion within chromosome 12q, and involving several different exons in each gene. STAT6 (signal transducer and activator of transcription 6) nuclear immunostaining and/or the identification of NAB2–STAT6 gene fusion is required for the diagnostic confirmation of solitary fibrous tumor. In the present study, a new gene fusion consisting of Nuclear Factor I X (NFIX), mapping to 19p13.2 and STAT6, mapping to 12q13.3 was identified by targeted RNA-Seq in a 74-year-old female patient diagnosed with a deep-seated solitary fibrous tumor in the pelvis. Histopathologically, the neoplasm did not display nuclear pleomorphism or tumor necrosis and had a low proliferative index. A total of 378 unique reads spanning the NFIXexon8–STAT6exon2 breakpoint with 55 different start sites were detected in the bioinformatic analysis, which represented 59.5% of the reads intersecting the genomic location on either side of the breakpoint. Targeted RNA-Seq results were validated by RT-PCR/ Sanger sequencing. The identification of a new gene fusion partner for STAT6 in solitary fibrous tumor opens intriguing new hypotheses to refine the role of STAT6 in the sarcomatogenesis of this entity.
Collapse
Affiliation(s)
- David S. Moura
- Institute of Biomedicine of Seville (IBiS, CSIC, HUVR, US), 41013 Seville, Spain; (D.S.M.); (J.D.-M.); (C.S.-A.)
| | - Juan Díaz-Martín
- Institute of Biomedicine of Seville (IBiS, CSIC, HUVR, US), 41013 Seville, Spain; (D.S.M.); (J.D.-M.); (C.S.-A.)
- Pathology Department, Hospital Virgen del Rocío, 41013 Sevilla, Spain
- Centro de Investigación Biomédica en Red del Cáncer (CIBERONC), 28029 Madrid, Spain
| | - Silvia Bagué
- Pathology Department–CIBERONC, Sant Pau Hospital, 08041 Barcelona, Spain; (S.B.); (R.O.-F.)
| | | | - Ana Sebio
- Medical Oncology Department, Sant Pau Hospital, 08041 Barcelona, Spain;
| | - Jose L. Mondaza-Hernandez
- Fundacion Jimenez Diaz University Hospital Health Research Institute (IIS/FJD), 28015 Madrid, Spain; (J.L.M.-H.); (N.H.)
| | - Carmen Salguero-Aranda
- Institute of Biomedicine of Seville (IBiS, CSIC, HUVR, US), 41013 Seville, Spain; (D.S.M.); (J.D.-M.); (C.S.-A.)
- Pathology Department, Hospital Virgen del Rocío, 41013 Sevilla, Spain
- Centro de Investigación Biomédica en Red del Cáncer (CIBERONC), 28029 Madrid, Spain
| | - Federico Rojo
- Pathology Department, Fundacion Jimenez Diaz University Hospital, 28040 Madrid, Spain;
| | - Nadia Hindi
- Fundacion Jimenez Diaz University Hospital Health Research Institute (IIS/FJD), 28015 Madrid, Spain; (J.L.M.-H.); (N.H.)
- Medical Oncology Department, Fundacion Jimenez Diaz University Hospital, 28040 Madrid, Spain
- General de Villalba University Hospital, 28400 Madrid, Spain
| | - Christopher D. M. Fletcher
- Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02215, USA;
- Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
| | - Javier Martin-Broto
- Fundacion Jimenez Diaz University Hospital Health Research Institute (IIS/FJD), 28015 Madrid, Spain; (J.L.M.-H.); (N.H.)
- Medical Oncology Department, Fundacion Jimenez Diaz University Hospital, 28040 Madrid, Spain
- General de Villalba University Hospital, 28400 Madrid, Spain
- Correspondence: ; Tel.: +34-95-540-2246
| |
Collapse
|